The Society of Thoracic Surgeons (STS) scores are used to screen patients for transcatheter aortic valve replacement (TAVR). The STS scores were also used to risk stratify patients in major TAVR trials. This study evaluates the reclassification of predicted risk of mortality by the currently available online STS score calculator compared with the 2008 STS risk model in patients undergoing TAVR.
stablished >3 decades ago, the Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database (ACSD) contains patient-related demographics, baseline comorbidities, procedural details, and other clinically relevant data for >6 million procedures performed by 3017 surgeons, which account for 90% to 95 % of all adult cardiac surgeries performed in the United States. [1] [2] [3] In addition to providing biannual reports to participating institutes as a national benchmark for quality measures, the Duke Clinical Research group, in collaboration with the Quality Measurement Task Force, used the ACSD to develop calculators for predicted risk of mortality (PROM) for major surgical procedures, including coronary artery bypass graft surgery and aortic and mitral valve procedures. [4] [5] [6] These models are maintained on the STS websites and have been used by cardiologists and other medical personnel as an objective method for risk assessment for patients requiring aortic valve replacement (AVR). Owing to the comprehensive nature of the database and the high reliability of the STS models, they have also been used extensively in major clinical trials to select patients who will benefit from transcatheter AVR (TAVR). The 2008 STS risk model was constructed using the STS ACSD (version 2.61) compiled during the years 2002 to 2006. 5 However, as the surgical outcomes for AVR improved over time, the STS database was also regularly updated, and the STS risk models have been revised. The most up-to-date STS risk calculator (as of February 2018) is available online and calculates PROM based on the STS ACSD, version 2.81, which was first used in 2014. 7, 8 Consequently, we hypothesized that among patients undergoing TAVR, the new STS risk model may classify the estimated PROM of some patients differently than the 2008 STS risk model. Further, specific subgroups of patients might have a greater change in STS scores than others.
METHODS
The data that support the findings of the study are available from the corresponding author on reasonable request.
Study Population
Clinical and demographic data were obtained from our prospective TAVR registry, which included all 1209 patients with severe symptomatic aortic stenosis (AS) who underwent TAVR between May 2006 and November 2016. Presence of risk factors and post-TAVR outcomes were assessed using the standardized definitions conforming to the definitions and standards of the STS. 5 The study protocol was approved by the Cleveland Clinic Institutional Review Board, data were deidentified, and informed consent was waived.
STS Score Calculation
The STS risk calculator is revised every few years to reflect the most recent updates of the ACSD. The STS risk models are constructed using the following formula 5 : where x 1 , x 2 …x π denote patient preoperative risk factors and β 0 , β 1 …β π denote regression coefficients. 5 The preoperative risk factors used in this formula are fixed in each version of the STS risk model, and regression coefficients are defined according to the latest ACSD. Therefore, the STS PROM can change according to the preoperative factors (ie, heart failure and diabetes mellitus) used in the model, and the regression coefficients change over time to reflect the current ACSD. The updated risk prediction algorithms are available on the STS website as online STS adult cardiac surgery risk calculators.
We calculated a 2008 PROM using the STS risk model for isolated AVR updated in 2008 (based on STS ACSD, version 2.61). 5 In brief, presence of preoperative risk factors like age, body surface area, atrial fibrillation (AFib), chronic heart failure, New York Heart Association class, chronic lung disease, cerebrovascular disease, diabetes mellitus, insulin use, dialysis, left ventricular ejection fraction, active endocarditis, female sex, hypertension, intra-aortic balloon pump or inotropes use, immunosuppressive treatment, peripheral vascular disease, number of previous cardiac surgeries, shock, status, mitral stenosis, unstable angina, and serum creatinine level were entered into the formula with regression coefficients to calculate the 2008 PROM. Current STS PROM was calculated with the same clinical information as mentioned above using the currently available online STS risk calculator for isolated AVR available February 2018 (based on STS ACSD, version 2.81). 9, 10 Of note, according to the updates in the STS risk model, computing PROM using the current STS risk model required additional preoperative risk factors like heart failure within 2 weeks preceding evaluation for AVR, presence
WHAT IS KNOWN
• Society of Thoracic Surgeons (STS) scores are used by heart teams to screen patients for transcatheter aortic valve replacement.
• STS scores have been used in major transcatheter aortic valve replacement trials to risk stratify patients included in these studies. 
WHAT THE STUDY ADDS

RESULTS
Patient Characteristics
The baseline characteristics of the study population are presented in Table 1 . The mean age was 81±9 years, and 696 (58%) patients were men, whereas 880 (73%) patients had chronic heart failure, 476 (39%) had history of chronic lung disease. 
Comparison of 2008 and the Current STS PROM
The overall mean PROM estimated by the 2008 STS risk model was 7.3±4.9%, whereas mean PROM by the current online STS risk model was 6.3±4.3%, showing a significantly lower value than the 2008 PROM (P<0.001). The current PROM showed a significant and strong correlation with the 2008 STS PROM (P<0.001; R=0.92; Figure 1 ). In a univariable Cox proportional hazards analysis, both the 2008 STS PROM (hazard ratio, 1.08; 95% CI, 1.02-1.13; P=0.01) and the current STS PROM (hazard ratio, 1.09; 95% CI, 1.02-1.15; P=0.02) were significantly associated with 30-day post-TAVR mortality. Further, both the 2008 and the current PROM had similar C index (Harrell C index, 0.60 for both). We then calculated the mean yearly PROM estimated by the 2008 STS risk model and again using the current STS risk model. When plotted against the year of TAVR, both the 2008 PROM and the current PROM showed a similar decrease in STS scores (P=0.005). However, the estimated PROM calculated using the current STS calculator was consistently lower than the 2008 PROM during the years (P<0.001; Figure 2 ). 
Overall Reclassification of Estimated Risk by the Current STS PROM
Reclassification of Estimated Risk by Current STS PROM in Patients With Specific Preoperative Risk Factors
In a multivariable logistic regression analysis, patients with AFib (odds ratio [OR], 1.42; 95% CI, 1.04-1.94; P=0.03), history of chronic heart failure (OR, 6.00; 95% CI, 3.75-10.14; P<0.001), and those with New York Heart Association class IV heart failure symptoms (OR, 2.39; 95% CI, 1.28-4.42; P=0.007) were more likely to be reclassified into a lower risk group per the current STS risk model (Table 2) . Patients requiring urgent AVR (OR, 0.11; 95% CI, 0.06-0.21; P<0.001) and those with an episode of heart failure within 2 weeks (OR, 0.23; 95% CI, 0.06-0.81; P=0.002) were less likely to be reclassified into a lower risk group by the current STS PROM.
Overall, the mean PROM calculated by using the current STS risk model decreased by a value of −1.0±1.8% in comparison with the 2008 STS PROM. When we assessed the changes in STS PROM according to the preoperative risk factors significant in the prior logistic regression model, patients with AFib and those with New York Heart Association class IV symptoms had a decrease in STS PROM ≥1.5% per the current STS risk model (Table 3 ). There was a minimal decrease of STS PROM in patients who required an urgent or emergent AVR and those who had an episode of heart failure within 2 weeks.
Interestingly, when compared with the 2008 PROM, the corresponding cutoff values of the current PROM for high-risk and intermediate-risk categories was found to be 6.3% and 3.9%, respectively.
Compared with the 2008 STS risk model, the current STS risk model reclassified 11 patients from intermediate risk to high risk, whereas 10 patients were reclassified from low risk to intermediate risk. We could not identify specific comorbidity associated to higher reclassification using the current STS risk model.
DISCUSSION
In this study, we calculated the PROM using the 2008 STS risk model and the current STS risk model among 1209 patients who underwent TAVR. The results of our study show that (1) when compared with the 2008 PROM, the current PROM showed lower mean STS values and reclassified a significant number of patients to a lower risk category; (2) when plotted against the year of TAVR, the PROM calculated by either model showed a decrease in STS scores over time; however, the PROM estimated by the current STS risk calculator consistently showed a lower PROM when compared with the 2008 STS risk model; (3) patients with a history of AFib, chronic heart failure, and those with New York Heart Association class IV heart failure symptoms were more likely to be reclassified into a lower risk group per the current STS risk model; and (4) when compared with the 2008 PROM, the corresponding cutoff values to classify patients into high-and intermediate-risk categories were lower when using the current STS model.
Reclassification of PROM by Current STS Risk Model
In a large cohort of patients undergoing TAVR, our study reveals that the current STS risk model reclassified a significant number of patients to a lower risk group. This decrease in STS PROM likely reflects the latest ACSD with improving surgical outcomes nationwide. 1, 11 The STS models assign a regression coefficient to all the preoperative risk factors used to calculate the PROM. 5 Additional risk factors in the current STS risk model might have redistributed these values. Moreover, improvement in surgical outcomes might have been more in certain risk groups of patients as evidenced by a much lower corresponding cutoff value for high-risk patients when compared with intermediate risk per the current PROM. Recently, post-TAVR outcomes among patients with diabetes mellitus have been shown to be better, whereas outcomes in patients with advanced kidney disease are similar to those undergoing an surgical aortic valve replacement. 12, 13 This disparity in outcomes indicates a different set of periprocedural risks associated with TAVRs when compared with surgical replacements of the aortic valve. Similarly, our data show that the current STS risk model reclassified patients with AFib to a lower risk category. However, AFib continues to be linked to a worse outcome among patients undergoing TAVR, whereas the absence of AFib has been linked to successful next-day discharges. 14, 15 Hence, screening strategies for TAVR should pay attention to certain preoperative risk factors, which may not be very important for patients undergoing surgical aortic valve replacement anymore. Interestingly, our data show that patients with heart failure who were highly symptomatic were more likely to get reclassified into a lower risk category per the current STS risk model, when compared with patients who had documentation of any heart failure within 2 weeks.
Our data are in line with previous reports that have indicated that the discriminatory power of STS scores to predict post-TAVR 30-day mortality is modest at best. 16 Because mortality rates associated with TAVRs in high-risk patients are still considerable, an accurate prediction of outcomes during patient selection is critical. 17 Notably, the discriminatory potential of the current PROM seems unchanged when compared with the 2008 PROM. This suggests that the STS models were not designed to predict outcomes in post-TAVR patients, and modifications in the STS models represent updates on an essentially surgical database. 18 Further, the PROM by either STS risk model was higher than the 30-day mortality rate observed in our cohort. Indeed, recent reports have indicated that surgical risk models like the STS risk models overestimate the mortality risk among patients undergoing TAVR. 19 Interestingly, a previous observation among 177 extreme-and high-risk patients who underwent TAVR during years 2008/2009 reported that 58% patients were reclassified from high risk to intermediate risk using the 2015 STS risk score. 20 The mean STS score reported in this report was much higher than the current study (11.6% versus 7.3%) and reflected patients undergoing TAVR during years 2008/2009. In comparison, we report that changes in STS scores reclassify patients in a contemporary TAVR population where patients undergoing TAVR include high-, intermediate-and even low-risk patients. We further identify patients with specific comorbidities that are more likely to get reclassified into a lower risk category using the current STS risk model.
STS Score in Major TAVR Trials
STS scores have been used to risk stratify patients in major trials involving TAVR. The PARTNER trial (Placement of Aortic Transcatheter Valve) included patients with severe AS in whom conventional surgery to replace the aortic valve was associated with high mortality risk as defined by an STS risk score of ≥10%.
21
The US Food and Drug Administration and the Centers for Medicare and Medicaid Services now mandate evaluation of potential TAVR patients using STS scores leading to a wider adoption of STS scores in clinical practice.
Piazza et al 22 reported a decrease in STS scores across enrollment periods (2006) (2007) (2008) (2009) (2010) , which suggests that younger and lower risk patents are receiving TAVR. Results from our study also show that patients with lower STS risk scores are getting enrolled in recent AFib indicates atrial fibrillation; AVR, aortic valve replacement; CHF, chronic heart failure; CLD, chronic lung disease; EF, ejection fraction; IABP, intraaortic balloon pump; NYHA, New York Heart Association; OR, odds ratio; PCI, percutaneous coronary intervention; and STS, Society of Thoracic Surgeons.
*Variables analyzed in model A: AFib, CHF, NYHA class IV symptoms, and urgent AVR. †Variables analyzed in model B: NYHA class IV symptoms, urgent AVR, heart failure within 2 wk, and paroxysmal AFib.
years. However, the mean yearly STS PROM estimated by the current STS calculator was consistently lower than the mean STS PROM calculated by the 2008 STS model. Interestingly, when we plot the reported mean STS values of major TAVR trials, the mean STS scores of patients in both high-risk and intermediate-risk trials decrease over time ( Figure 4A ). 21, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] In our study, the optimal intermediate risk cutoff value for the current STS PROM was found to be 3.9% (compared with 4% per the 2008 STS PROM). However, the decrease in the corresponding high-risk cutoff by the current PROM was found to be even more significant at 6.3% (compared with 8% per the 2008 PROM). These findings indicate that we are performing TAVRs on a cohort of patients who have an overall higher risk of mortality, despite the lower STS scores generated by the newer STS risk calculators. Indeed, a regression line generated by recalculating published STS scores per the current risk model shows a lower overall decrease in STS scores during the years ( Figure 4B , dotted green regression line). Notice that the gap between the regression lines generated from the reported and recalculated STS scores decreased in recent years indicating the use of more recent versions of the STS models in the later years.
Taken together, our study indicates that the clinical profiles of patients enrolled in previous TAVR trials may be different from the patients we encounter in clinical practice today, even if they have similar STS scores. Moreover, patients who are now being enrolled as intermediate risk may have been classified as high risk in previous trials. Indeed, there might be a need to change the paradigm to low-and high-risk groups and not classify patients into an intermediate group.
It is also becoming apparent that STS scores may provide insight into surgical aortic valve replacement risk but not TAVR risk; however, how the newer versions of STS risk models perform in this regard is not well documented.
Clinical Perspectives
STS scores are being used by heart teams to screen patients with severe AS in an era where of TAVRs are an attractive alternative to surgical valve replacement in patients with a high or intermediate risk of perioperative mortality. However, it is important that physicians use their clinical judgment using a multidisciplinary team approach while screening patients for TAVR because the PROM generated by the current STS risk calculator may misrepresent the data generated from previous TAVR trials. Although the mean STS scores of patients being enrolled for TAVR have been decreasing over time, patients classified as having intermediate risk in today's clinical practice might have a higher risk than thought previously. Hence, anatomic and clinical characteristics of patients should be taken into consideration by heart teams for judging TAVR risk.
Limitations and Future Directions
Although the data presented here are from a large cohort of TAVR patients, with an enrollment period spread across a decade, with only 27 (2.2%) observed perioperative deaths, we were limited in our ability to examine the calibration of the STS scores to predict 30-day mortality risk. Furthermore, the observed 30-day mortality in our study (2.2%) was much lower than the PROM estimated by the current (6.3%) or the 2008 STS risk model (7.3%). This indicates a growing need to adopt and validate TAVR-specific risk models in large prospective multicentric trials, taking into account frailty, cognitive status, and other clinical characteristics for accurate risk profiling of patients with severe aortic stenosis. Furthermore, since the STS ACSD started collecting data under version 2.9 since July 2017, further investigation will be needed once the new risk model becomes available online. Lastly, although we observed a lower high/intermediate-risk threshold for the current STS model when compared with the 2008 STS model, determining new cutoff values by comparing the 2 STS risk models using a logistic regression analysis might be misleading.
Conclusions
Among patients who underwent TAVR, the current STS risk model estimates significantly lower PROM when compared with the 2008 STS risk model. Additionally, a significant number of patients were reclassified into a lower risk category per the current STS calculator. Patients 21 Smith et al, 23 Reardon et al, 24 Haussig et al, 25 Herrmann et al, 26 Thourani et al, 27 Leon et al, 28 Meredith et al, 29 Popma et al, 30 Adams et al, 31 Abdel-Wahab et al, 32 and Stabile et al.
